A significant trend toward an increase in Ki67 + CD8 + T cells in the periphery on cycle 2, day 1 with increased AZD8701 dose was noted, indicating potentially enhanced activation of cytotoxic T cells.
← all excerpts
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.
1
—
—